2019
Anti-Müllerian Hormone and its Predictive Utility in Assisted Reproductive Technologies Outcomes
GRANGER E, TAL R. Anti-Müllerian Hormone and its Predictive Utility in Assisted Reproductive Technologies Outcomes. Clinical Obstetrics & Gynecology 2019, Publish Ahead of Print: &na;. DOI: 10.1097/grf.0000000000000436.Peer-Reviewed Original ResearchAnti-Müllerian hormoneART outcomesOvarian responseAssisted Reproductive Technology OutcomesControlled ovarian stimulationReproductive technology outcomesInformative biochemical markersHyperstimulation risksOvarian stimulationClinical utilitySensitive markerStimulation protocolBiochemical markersReproductive agingTechnology outcomesOutcomesHormonePredictive utilityBest predictorMarkersResponse
2014
Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome